Shots: AcelRx acquires Tetraphase in an all-stock transaction, at an exchange ratio of 0.6303 shares of AcelRx for each share of Tetraphase, or ~$14.4M as of Mar 13, 2020 and […]readmore
Tags : Product Portfolio